Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NURIX THERAPEUTICS, INC. reported revenue of $84M, up 54.0% year over year. Operating margin was -340.2% and net margin -314.9%, on a free-cash-flow margin of -313.7% with capital expenditure at 16.7% of revenue. Every figure is computed directly from NRIX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $84M | -340.2% | -314.9% |
| FY2024 | $55M | -390.5% | -354.9% |
| FY2023 | $77M | -201.4% | -187.0% |
| FY2022 | $39M | -476.0% | -466.9% |
| FY2021 | $30M | -396.3% | -393.9% |
How does NRIX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.